The “Nature” journal published a research study last week that highlights the discovery of meninges to be home to plasma cells, which are immune cells that secrete antibodies. These cells are positioned near large blood vessels running in the meninges, which allows them to secrete antibodies that defend the brain’s perimeter.

For a long time, scientists couldn’t decipher how the brain remained protected against invading viruses and bacteria. However, a team of researchers led by scientists at the National Institute of Health in the United States and the University of Cambridge in the United Kingdom, have discovered that the specific antibody type produced by these cells was the type found in the intestine.

Plasma cells originate from an immune cell known as a B cell. Each B cell has a surface antibody unique to that specific cell. If an antigen, i.e., a virus or bacterium that triggers an immune response, binds to the antibody on its surface, the B cell activates. It will do this by dividing to create a new offspring that also recognizes the same antigen.

During division, a mutation is introduced into the antibody gene by the B cell that changes the binding characteristics of an amino acid. Several B cells then produce antibodies that allow better binding to the pathogen. These continue to expand and multiply, with B cells having antibodies that aren’t good at binding ultimately being eliminated. This helps make sure that the body produces the best antibodies for picking out and eliminating particular antigens.

Antibodies found in the meninges include immunoglobulin A, which is normally made in the lining of the lungs, nose or gut. The team of researchers sequenced the plasma cells in the meninges and the gut as well as the antibody genes in the B cells. They discovered that these cells were related. Professor Menna Clatworthy, the lead scientist from the Department of Medicine at Cambridge explained that it had been a mystery to scientists how the brain protected itself from infections, so discovering that the line of its defense originated from the gut was surprising.

The researchers made this discovery using mice, which are commonly used to study physiology because they share characteristics similar to humans. The findings of the study demonstrate that the immunoglobulin A cells were absent in the meninges when mice had no bacteria present in their guts. When the researchers removed plasma cells from the meninges, microbes spread into the brain from the bloodstream.

The team then analyzed samples that had been extracted during surgery and confirmed that immunoglobulin cells were present in human meninges, thus showing that this defense system played an important role in defending people from infections of the central nervous system, such as encephalitis and meningitis.

AzurRx BioPharma Inc. (NASDAQ: AZRX) is a clinical-stage biopharmaceutical firm that you should follow. The compamy focuses on using recombinant proteins to develop novel solutions for gastrointestinal diseases.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• HempFusion’s current product offerings, already available in stores, include tinctures, capsules, OTC topicals, edibles, probiotics and a doctor/practitioner line
• The company abides by all FDA regulations for its full line of products. It is one of few companies marketing FDA Drug Listed Topicals
• HempFusion is currently one of 12 CBD companies conducting a study addressing FDA concerns regarding CBD products and human safety
• The significant time and capital invested in HempFusion’s compliance provide the company with a competitive advantage in the expanding CBD market
• The CBD sector is projected to reach $16.8 billion by 2025
• The company has the second-largest cash presence in the market at $18.3 million as of June 30, 2020, and it is preparing to launch an IPO and list on the Toronto Stock Exchange under ticker symbol ‘CBD.U’

HempFusion Wellness is a leader in the health and wellness CBD industry, providing innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition.

Invested heavily in regulatory compliance, HempFusion aims to consistently meet and even exceed the high standards required by retailers and consumers – putting safety, quality and consistency first. In support of these efforts, the company is U.S. Hemp Authority Certified and is a current board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products.

HempFusion reported 1,750 shareholders and $18.3 million in cash as of June 30, 2020 – the second-largest cash position in its sector – with no debt. Looking ahead, the company is currently preparing to launch an IPO directly onto the Toronto Stock Exchange (“TSX”) senior board, where it has already reserved ticker symbol ‘CBD.U’. Learn More About HempFusion Upcoming IPO.

HempFusion is headquartered in Denver, Colorado.

HempFusion’s Proprietary Wellness Portfolio

The diverse product portfolio showcased by HempFusion includes 46 products that are currently on shelves. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Due to the time and resources allocated to increasing the compliance of these proprietary products, HempFusion may have a competitive advantage and create additional retail opportunities that are not available for other CBD companies.

HempFusion’s Diversified Revenue Pipeline

HempFusion’s focus and investment into regulatory compliance has opened doors to major food and drug mass or big box retailers that are not available to other CBD companies. This strategic approach includes five distinct channels:

• Natural Health Retailers
• eCommerce
• Big Box / Food and Drug Mass
• Doctor Practitioner
• Convenience

HempFusion’s Line of Products

HempFusion’s branded line of products is based on the company’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex. Each product is condition-specific, targeting needs such as sleep, energy and stress.

All of HempFusion’s products are made from DNA-verified, European Union registered, non-GMO, organic industrial hemp. The company’s offerings span multiple product categories, including:

• Tinctures and capsules – These offerings make up the most popular product category in the $4 billion U.S. CBD market.
• OTC topicals – HempFusion is one of the few CBD companies marketing FDA Drug Listed Topicals. The FDA compliance standards ensure that these products meet the standards set by larger national retailers.
• Condition-specific OTC products – HempFusion has OTC products that are condition-specifically targeted, including:

• • OTC Pain Products – The global pain relief market for topicals is projected to reach $13.3 billion by 2025, with a CAGR from 2018 to 2025 of 7.4%.
  • OTC Eczema Products – The global dermatitis market is projected to reach $13.6 billion by 2026.
  • OTC Acne and Aging/Beauty Products – The global market for beauty and anti-aging products is currently estimated at $1.08 trillion.
  • OTC First Aid and Wound Healing Products – In 2019, the 10 top-selling first aid ointments in the United States generated over $650 million in sales.

Probulin Probiotics and Digestive Enzymes

Probulin Probiotics is a 100% wholly owned subsidiary of HempFusion Wellness Inc. and is currently one of the fastest growing probiotics brands in the United States, according to Spins syndicated data.

The Probulin product line addresses a wide range of consumer needs, including daily care, total care, women’s health and children’s products. The probiotics market represents a growing opportunity, as it is estimated to reach $7 billion globally by 2022.

Because of the diverse offerings of the Probulin line, it serves as HempFusion’s gateway to retailers who may not currently carry CBD products.

This ‘Trojan Horse Strategy’ is intended to allow the company to establish, develop and build relationships among these retailers. By achieving approved vendor status, the company may be able to facilitate faster onboarding times, enabling accelerated access to its CBD products in the future.

HF Labs and Biome Research – Doctor and Practitioner Product Lines

The HF Labs and Biome Research product lines are directed toward doctors and practitioners and cater to hospitals, compounding pharmacies and free-standing dispensaries. With an estimated target market of 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, these offerings create a unique market opportunity as HempFusion continues to broaden its footprint in the CBD industry.

Research on CBD and Human Safety

HempFusion is one of 12 CBD companies selected to participate in ValidCare’s groundbreaking study regarding CBD and human safety, which is expected to be complete by the end of October 2020. The study is designed to address previous questions from the FDA regarding CBD products.

As part of this study, HempFusion and the other selected companies will be conducting human trials to determine if the daily use of full-spectrum hemp-derived CBD or CBD isolate impacts the human liver.

Management Team

Jason Mitchell, N.D., is the co-founder, Director and CEO of HempFusion. He has over 20 years of experience in the natural products industry and is a naturopathic doctor certified by the ANMCB. Mitchell received his doctorate from the Trinity College of Natural Health and is a member of the American Naturopathic Medical Association and the CNHP. He is an expert in supplemental formations and was responsible for successfully creating and launching over 300 industry-leading products during his 15-year tenure at Country Life Vitamins.

Ian DeQueiroz is the Chief of Brand Strategy & Partnerships and a Director for HempFusion. He is a serial entrepreneur with experience in early-stage cannabis and hemp companies. In 2010, he acquired his first cannabis CO2 extraction company in the United States. DeQueiroz has facilitated the licensing process for many companies in the United States, as well as one of Jamaica’s premier cannabis companies, Epican Medicinals Ltd.

Jon Visser is HempFusion’s Chief Revenue Officer. He has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multi-national manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Bruce Valentine Jr. is the Chief Financial Officer of HempFusion. He has a proven track record working with high-growth companies and was named CFO of the Year in 2013 by the Northern Colorado Business Report. Valentine is the former CFO of Otter Products and has over 15 years of financial management experience.

Ola Lessard is the Chief Marketing Officer of HempFusion and is also the President of the U.S. Hemp Roundtable. She has experience in marketing creative and effective brand strategies. She is a former Vice President of Marketing at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini is the Director of the Doctor/Practitioner Channel. She has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody is the Chief Corporate Officer of HempFusion. He is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF). Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.

For more information, visit the company’s website at www.HempFusion.com.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://nnw.fm/HempFusion

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Face masks, as we have seen, have been effective in filtering out the SARS-CoV-2 virus, thus reducing the risk of a coronavirus infection. A group of scientists from MIT now aim to develop a mask that uses heat to inactivate viruses.

These innovative masks will have a built-in, heated copper mesh. When an individual who is wearing the mask breathes in and out, the air flows across the mesh repeatedly, which slows and inactivates any viral particles in the air using high temperatures and the mesh. The researchers state that this mask could be useful for health-care providers as well as people who are in places where social distancing is hard to achieve, such as on crowded buses.

A professor of chemical engineering at MIT, Michael Strano, who is also the senior author of the paper, says the mask is based on a new concept that inactivates the virus instead of blocking it, which is what current masks do. The team is currently building the prototypes and hopes to start conducting tests on the masks soon. In a paper posted to on ArXiv, the team describes its design and revolutionary concept.

The paper’s lead author is Samuel Faucher, an MIT graduate student. Other authors of the paper include Jacopo Buongiorno, an MIT professor of nuclear science and engineering; Xiaojia Jin, Xinyao Liang and Daniel Lundberg, who are all MIT graduate students; Dorsa Parviz, a postdoc; and undergraduate Rosalie Philips.

Buongiorno and Strano began looking into concepts for new types of face masks earlier in March. After discovering no masks were designed to kill viruses using heat, the group started designing a mask that would do the job. The team members settled on copper as the capture and heating element and then carried out some mathematical modelling designed identify the optimal temperature range required to kill the coronaviruses flowing outward or inward from natural breathing.

While a majority of the masks used today work by filtering particles by electric charge or size, this new mask design would function by thermal inactivation and rely on a different mechanism. After the virus is inactivated, the air is cooled to make the mask safe to use and comfortable.

Furthermore, the masks do not need to be disposed of after use nor do they require decontamination. This is mainly because, unlike the masks used today, such as cloth masks, surgical masks and N95 respirators, the virus is killed. The masks also offer extra protection because they eliminate the virus instead of filtering it out.

The researchers point out that, although the masks will be more expensive, they will be more useful in high-exposure situations when compared to normal masks, which makes cost a small concern.

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is an entity you should watch in the biomed sector. The company focuses on identifying conditions for which clinical efficacy evidence is available and then develops therapies to address those unmet needs.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competition
• Results garnered from company’s HSC optimization are unparalleled in field
• Soluble Biotech lands first major contract, signifying major company milestone

Offering a proprietary automated High Throughput Self-Interaction Chromatography(TM) (“HSC”) Technology Platform, Predictive Oncology (NASDAQ: POAI) provides biomedical and pharmaceutical companies with superior options never before available. A knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, POAI, through its subsidiary Soluble Biotech, delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations.

HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations (https://ibn.fm/vbZ53). The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination of additives and excipients, resulting in increased solubility and physical stability of proteins. And while the technology produces unparalleled optimization results, it provides other benefits as well.

Using current methods, optimization can take more than a year, cost hundreds of thousands of dollars and require teams of five or more individuals to complete. Optimization with HSC, on the other hand, takes only three months, costs tens of thousands of dollars, and needs just one individual to conduct. The comparison is stark — and irresistible. Soluble Biotech has already finalized its first substantial contract since being acquired by POAI earlier this year and is currently negotiating additional contracts (https://ibn.fm/iuo4O).

“Our first contract is a major milestone and validates our recent move into a new, larger facility,” said Soluble Biotech founder Dr. Larry DeLucas, who is also a former NASA astronaut. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies.”

A provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes, Soluble Biotech is fast becoming recognized for its expertise in enhancing the drug-development process by rapidly optimizing protein solubility and stability. The company brings proprietary transformational technology to formulation development for protein-based pharmaceuticals and vaccines. In addition, its solubilization and stability technology is used at academic, pharmaceutical and government laboratories involved in conducting fundamental protein research.

Soluble Biotech’s exclusive HSC technology was developed by Dr. William Wilson, a former chairman of the chemistry department at Mississippi State University, and DeLucas; the two have spent almost 20 years developing the game-changing technology and tool. HSC has been validated over the past decade through numerous industry and academic collaborations with several clients seeing tenfold and even hundredfold increases in their protein’s solubility while also maintaining physical stability. For the pharmaceutical sector, this means faster development times and quicker progression of molecules into the clinic. In academics, these results lead to further progression of biochemical and biology studies that are vital to advance fundamental research in areas of unmet medical need.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Despite its relative novelty, the electric vehicle (“EV”) industry has made tremendous strides towards cleaning up our roads. Transportation accounts for approximately 28.2% of greenhouse gases worldwide, and several governments are planning on phasing out internal combustion engine vehicles in favor of electric vehicles over the next decade or two to address this. Not only do EVs run on clean, renewable energy, they also produce zero emissions at the tailpipe, making them the perfect vehicle for a net-zero economy.

However, we are still a long way from widespread EV adoption. Most consumers are put off by the sometimes very high prices as well as spotty and insufficient charging infrastructure. Installing a home charger makes the initial investment even higher. EV drivers who rely on street chargers often report too few chargers or too many that require multiple subscription-based memberships, apps and cards, resulting in a frustrating and time-consuming charging experience.

Energy companies are in perhaps the most unique position they’ve been in in a long time, seeing as electric vehicles, which are poised to take over the roads over the next decade, are powered entirely by rechargeable batteries. One thing energy suppliers could do to boost EV adoption would be to leverage existing energy infrastructure to aggregate consumption and pass that consumption through to consumers in one bill. This would eliminate the need for multiple subscriptions, apps and cards.

Thanks to the nationwide installation of SMETS2 (Smart Meeting Equipment Technical Specifications) smart meters, energy suppliers have a whole lot of data on their hands. These meters send meter readings automatically to energy suppliers, allowing them to obtain a better idea of their customers’ energy needs and charging habits. This data could be used to create a variety of propositions to boost EV adoption, such as time of use (“ToU”), that allow energy suppliers to decrease individual carbon emissions by helping customers identify how much carbon they use at certain times.

Additionally, energy suppliers could also partner with automakers and offer customer management and specifically designed tariffs for the EV’s life cycle of ownership. This support could also be in the form of discounted charging, innovative upgrades, and the ability to use multiple charging companies through one membership system. EV makers could also decide to go into the energy supply business themselves, leveraging the data they collect from EV drivers to create better-aligned propositions.

In the long term, such data could be used to develop smart charging algorithms, solve energy efficiency issues, develop policies for charging stations, and evaluate the capacity of power distributions systems to handle extra charging loads.

Net Element (NASDAQ: NETE) is one interesting company you should watch in the electric vehicle space. The global financial solutions provider is merging with Mullen Technologies Inc., a lightweight commercial EV maker.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

In order to eliminate tumors while strengthening a cancer patient’s immune system, health providers administer cancer immunotherapies to patients. Immunotherapy is revolutionizing the treatment of cancer as many patients respond very well to these treatments, with some actually experiencing a long-lasting remission. However, some types of cancer aren’t as easy to treat with this method, which is why enlarging the effect of this approach remains a high priority.

A team of researchers led by Douglas Fearon and Tobias Janowitz, both scientists from Cold Spring Harbor Laboratory, may have found a way to do this. In collaboration with the University of Cambridge and Duncan Jodrell of the Cancer Research UK Cambridge, the scientists conducted a clinical trial of a drug that causes an integrated immune response in patients with tumors of cancer types that do not normally respond to immunotherapy.

The trial was reported in “Proceedings of the National Academy of Sciences.” The scientists are hopeful that the potential treatment may make tumors more responsive to immune checkpoint inhibitor drugs. These drugs release the natural brakes on an individual’s immune system, thus freeing it to locate and eliminate cancer cells. However, these same drugs haven’t been effective in destroying cancer cells that have low levels of genetic mutation.

Janowitz explained that these tumors are not visible to a person’s immune system and aren’t unmasked by the current therapies being used. The scientists believe that this is because they engage an immune suppressive pathway, which prevents immune cells from accessing the cancer cell nest.

During the clinical trial, the scientists cut off that immunosuppressive pathway using a drug known as plerixafor. The drug was dispensed continuously via IV for seven days to 24 patients who had either colorectal cancer or pancreatic cancer with a low tumor mutational burden. All 24 participants had advanced in the disease stages and had biopsies of their metastatic tumors collected both before and after treatment.

The researchers then analyzed those samples and discovered that critical immune cells had invaded the tumors during the period the patients were receiving plerixafor. Among those immune cells was a cell type whose role was to mobilize and assemble anti-cancer cells. These findings were encouraging to the researchers, who also noted changes had been observed in patients who had cancers that responded positively to checkpoint inhibitors.

Jodrell, who was in charge of patient recruitment and planning for the clinical study, stated that he was pleased to learn that the research team had translated these valuable discoveries into patient care that has potential to revolutionize how these cancers were treated in the future.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is one of the interesting entities that you should watch in the biomedical technology space. This company, whose headquarters are in Houston, Texas, focuses on developing new treatments for both primary and metastatic forms of cancer affecting the central nervous system and the brain.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Plant-based superfood developer Rritual Mushrooms Inc. has produced its initial product lineup of three functional mushroom elixirs and powders designed to boost personal wellness
• The company was recognized by retail marketing agency ECRM for its attractive product presentation and growing success, as judged by national outlets including CVS, Vitamin Shoppe, Amazon and Rite Aid
• The functional mushroom market is a nascent subsection of the wellness industry ripe with potential for companies that get in on the ground floor as expectations for the industry grow
• Rritual’s Reishi Relax, Chaga Immune and Lion’s Mane Focus formulations are available in 14-stick packs and in 250-gram tubs, as well as in a 14-day variety pack that includes all three elixirs

Lifestyle therapeutics innovator Rritual Mushrooms gained recognition for its development of attractive marketing and its growing market presence at the 2020 annual ECRM Buyer’s Choice Awards.

The awards spotlight Efficient Collaborative Retail Marketing, and Rritual Mushrooms achieved second place in the Whole Body & Mind Wellness category, which was voted on by wellness product buyers from national retail outlets in a virtual event last month (https://nnw.fm/r2IWr).

“Rritual’s performance at the ECRM Buyer’s Choice Awards was not only a vote of confidence for the long-term potential of our product line but also a clear indication that there is strong demand for high-quality and accessible mushroom products among mainstream consumers and retailers alike,” Rritual’s CEO David Kerbel stated.

Rritual Mushroom is a premium brand in the functional mushroom market, an industry that is still in its infancy and ripe with potential for early movers. Certain mushrooms have long been touted for their beneficial properties — as an example, the Reishi mushroom enjoys a reputation as “the mushroom of immortality” after thousands of years of use in traditional Chinese medicine for boosting the immune system, fighting off cancer, fatigue and depression, supporting heart health, and helping to control blood sugar levels (https://nnw.fm/yyP8U).

Rritual has introduced an initial product line of elixirs, shots and mixes for three mushroom varieties paired with select adaptogens — herbal substances used to increase the body’s ability to resist biological stress (https://nnw.fm/Tw4em). In addition to Reishi, which is paired with the adaptogen Ashwagandha root, Rritual’s products pair the Chaga mushroom with Eleuthero root and the Lion’s Mane mushroom with Rhodiola root.

“I believe Rritual has a great business model and product portfolio, in addition to a talented and passionate management team that uniquely positions it for success in the emerging plant-based industry,” Dr. Mike Hart, the company’s new president stated when he was hired in June (https://nnw.fm/mYsDZ). “Their mission to help people adapt to modern life and prove that mushrooms are one of the world’s greatest superfoods is a perfect fit with my own wellness practices as a physician, and personally as an individual who is passionate about mental and physical health.”

Each Reishi Relax, Chaga Immune and Lion’s Mane Focus elixir also contains a blend of six functional mushrooms including turkey tail, shiitake and maitake, as well as a prebiotic blend featuring inulin and lucuma fruit powder, which together are designed to support immune and digestive health.

ECRM VP of Health and Beauty Care Craig Chmielowicz noted the timeliness of Rritual’s product offering, stating, “A big part of wellness these days — especially during the pandemic — includes finding ways to relax the body and mind” (https://nnw.fm/Aimws).

For more information, visit the company’s website at https://Investors.WeAreRritual.com.

“Mental Fitness is a Daily Ritual”

NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• VistaGen has three innovative CNS drug candidates which target a wide range of anxiety, depression and neurological disorders
• PH94B, the Company’s most advanced drug candidate, is entering Phase 3 development for acute, on-demand treatment of social anxiety disorder
• Company sees potential to displace benzodiazepines currently being used to treat multiple anxiety disorders
• Strategy has gained in importance after U.S. FDA announced in late-September its update requirement for boxed warnings on all benzodiazepines to highlight risks of abuse, misuse, addiction, and physical dependence
• Benzodiazepine epidemic is as worrisome as the opioid epidemic – 92 million benzodiazepine prescriptions in 2019 according to the FDA

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications which go beyond the standard of care for anxiety, depression, and several neurological disorders. The company’s product portfolio consists of three novel drug candidates which seek to target a wide variety of central nervous system (“CNS”) disorders through medications with potential to not only be effective but also present fewer side-effects and safety concerns relative to the current standard of care. Its initiative relating to anxiety disorders has unique potential to pay dividends following recent actions taken by the U.S. Food and Drug Administration (“FDA”) involving benzodiazepines, a class of drugs widely used to treat anxiety disorders, as well as insomnia and seizures.

In late September 2020, the FDA announced that it would require the boxed warning on all benzodiazepines to be updated to describe the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions consistent to all medicines in this class (https://ibn.fm/sHdvF).

A review carried out by the FDA found that benzodiazepines were widely prescribed in the U.S., with 92 million prescriptions in 2019, often for extended periods of time. The study also found that benzodiazepines were widely abused and misused, often together with alcohol, prescription opioids, and illicit drugs—all of which could result in serious issues. Separately, the FDA study also revealed that some patients were found to have suffered serious withdrawal reactions after benzodiazepines were stopped suddenly or the dose reduced quickly, with a significant minority experiencing difficult withdrawal symptoms for several months.

With its lead drug candidate, PH94B, entering Phase 3 development in 2021, VistaGen Therapeutics is focused on displacing benzodiazepines in the treatment paradigm for the acute treatment of social anxiety disorder, as well as many other anxiety disorders.

The global CNS therapeutics market is estimated to reach $130 billion by 2025 and has been forecast to grow at a CAGR of more than 5.93% between 2018-2025. A rise in mental illnesses and increased awareness of psychiatric disorders (https://ibn.fm/I0JiR), conditions which have been exacerbated during the COVID-19 pandemic, have been calculated to cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://ibn.fm/53t2R).

The impact of mental health disorders on patient lives and the wider global economy, coupled with the potential risks associated to conventional benzodiazepine drugs, have increased the urgent need for pharmaceutical companies to develop more effective and safer alternatives to the current standard of care available to patients today. As such, VistaGen has taken it upon itself to help address the millions of underserved patients suffering from anxiety and depression disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders (https://ibn.fm/UyTmK).

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

More than a century ago, the Spanish flu pandemic spread across the globe, claiming the lives of an estimated 50 million people. Unlike today, there were no mechanical ventilators, diagnostic tests or anti-inflammatory medications apart from aspirin. The first vaccines of the diseases weren’t even available until 1936, almost two decades after the destruction of the Spanish flu.

According to forecasts by the Imperial College London, approximately 1.3 million people will succumb to the coronavirus this year. Many factors have reduced the mortality rates of the disease, including advanced technology and better execution of social-distancing measures.

In the United States alone, about $50 billion has been spent since January to increase the testing, diagnosis, vaccine creation and treatment of COVID-19. While many countries are still battling the pandemic with lockdown measures in place, others have fully contained the virus and are well on their way back to normalcy.

Many lives have been lost around the globe due to incompetence and lack of relevant measures in place. To ensure that this is avoided in the event of a future pandemic, here are a few ways we can prepare for such an eventuality.

• Investing in cutting-edge technologies

As we have seen, technology has not only prevented many from dying due to coronavirus-related complications but has also tremendously sped up the development of both antiviral drugs and vaccines. Unlike normal vaccine development, which may take years, developing a COVID-19 vaccine has become a race between the virus and humans. With at least 17 coronavirus vaccine candidates in clinical trials, barely months after the first recorded case, it’s clear that technology will not only endure but it may even be the key to a far more effective response in the event of a future pandemic.

• Look into digital contact tracing

There are two main things that differentiate the successful responses in Asian countries such as Korea, which managed to contain the virus, and countries such as the United States, which failed to respond correctly at the pandemic’s onset: contact tracing and testing.

Testing was too inaccurate and unavailable in the U.S. when it was most needed. With results taking two weeks for confirmation, the disease rapidly spread. To help prevent this from re-occurring in the future, researchers should develop a system that allows rapid testing on a large scale and takes a short time to produce results.

Not to say things were rosy on the other side though. Despite the successful containment rate in Asian countries, it came at the price of people’s privacy. Through digital contact tracing, countries such as South Korea and China were able to rapidly suppress the viral disease, using smartphone apps that tracked the movements of individuals.

While this method is intrusive, it has proven to be effective. For the future, researchers should come up with solutions based off of this method but tailored to be less-intrusive. It has been proven that almost all major infectious outbreaks in today’s world are brought about by zoonotic transfer. This is when the pathogen is transmitted from an animal to a human. With other factors such as the growth in livestock farming and loss of natural habitats at play, animal populations are coming into more contact with people.

It may be hard to slow or stop these global trends, so to mount a robust response for future pandemics, countries should ensure that communities are well informed on everything related to the outbreaks, that good governance is employed and measures are put in place (a contingency plan if you may), and that suitable technology is available.

One interesting entity you need to watch in the biomedical field is Predictive Oncology (NASDAQ: POAI). The company’s singular focus is to apply data and artificial intelligence in the quest for personalized medicine in the treatment of different cancers.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Knightscope is a leader in the development of autonomous security capabilities and is on target to disrupt the $500 billion security industry
• The company is presently in the process of raising up to $25 million in additional growth capital as it prepares for a possible public listing
• With more than 16,000 investors, over $70 million raised since inception and several Fortune 1000 clients with prepaid contracts, Knightscope is poised to be an industry leader in the future of public safety and security
• The company has opened investing to the public through its latest Reg A+ offering at $10 per share
• This innovation has the potential to drive cost savings and profitability for clients; manufacturing costs can be recovered as soon as the first year of operation
• The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs; the machines’ embedded thermal scanning capabilities also aided in preventing the breakout of a major fire

Knightscope Inc., founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities on target to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics and artificial intelligence.

Knightscope designs and builds Autonomous Security Robots (“ASRs”) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country, despite the pandemic (note: robots are immune).

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.Knightscope.com/Crime

The company has achieved several milestones since its creation in 2013, including:

• Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology;
• Operating for more than one million hours in the field and securing contracts across five time zones;
• Navigating through the global pandemic without interruption by continuing to operate on a daily basis across the nation and supporting clients classified as essential services; and
• Continuing its hiring processes despite the current societal and economic disruption.

Growth Capital

With backing from more than 16,000 investors and four major corporations and over $70 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

The company is presently in the process of raising up to an additional $25 million in growth capital as it prepares for a potential public listing. Knightscope has reserved ticker symbol ‘KSCP’ with Nasdaq.

Investors can buy shares exclusively through the company’s managing broker-dealer, StartEngine.

Knightscope’s latest Reg A+ offering is for up to 2.5 million shares of Series S preferred stock convertible into shares of Class A common stock at a price to the public of $10 per share.

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Crime has a negative economic impact in excess of $1 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was recently interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one to one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $4 to $11 per hour, compared with approximately $85 and $30 per hour for an armed off duty law enforcement officer and an unarmed security guard, respectively.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has eight patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’.

The ASRs and all the related technologies were developed ground up by the Company and are Made in the USA.

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

For more information, visit the company’s website at www.Knightscope.com

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://nnw.fm/Knight

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

In a study published last week in “Nature Medicine,” a group of researchers from the Scripps Research Translational Institute discovered that wearable fitness devices may improve public health efforts to control the coronavirus.

The data analyzed was collected in the DETECT study, which was launched on March 25. The smartphone app gathers activity tracker and smartwatch data from consenting participants. It also collects the participants’ self-reported symptoms as well as diagnostic test results. Any adult living in the United States can participate in the study; all you have to do is download the MyDataHelps app.

The team noted that devices such as the Fitbit are able to identify coronavirus cases by simply assessing an individual’s heart rate, changes in sleep and activity levels and self-reported symptoms. Founder and director of the Scripps Research Translational Institute Eric Topol states that with about 100 million Americans already in possession of a smartwatch or wearable tracker, all that’s left is getting a small fraction of them — he estimated 2% — to use the app. This will allow the researchers to use the data to contain emerging outbreaks.

The data collected from the app will also allow researchers to note when participants deviate from their normal range for resting heart rate, activity level or sleep, as these deviations may be a sign of an infection or viral illness.

The question: How will researchers know if the illness behind these changes is COVID-19? To answer this, the researchers analyzed data from participants who were tested for the coronavirus or had reported developing symptoms of the viral infection. Knowing the results of the tests allowed the researchers to identify any specific changes that may indicate a COVID infection or other ailments.

The first author of the study, Giorgio Quer, explained that one of the biggest challenges in stopping the novel coronavirus infection from spreading was the ability to quickly pick out, track down and isolate infected persons. He notes that identifying individuals who may be asymptomatic or presymptomatic would be valuable, as individuals are likely to be more infectious during this period.

The study, which used data from wearable devices, could pinpoint with an 80% accuracy whether an individual had COVID-19. Significant factors that were considered in predicting the infection included less activity and more sleep. Study lead Jennifer Radin states that because common screening practices for COVID-19 may miss asymptomatic or presymptomatic cases, enrolling more participants in the research — she noted more than 100,000 individuals — would help researchers improve their predictions of individuals, including asymptomatic people, who will get sick.

DarioHealth Corp. (NASDAQ: DRIO) is an interesting company in the biomed technology space that you should watch. The company is a leader in digital therapeutics, and since the vast majority of chronic illnesses, such as diabetes and hypertension, can be prevented by using behavioral therapies, the smartphone-based, behavioral change solutions developed by DRIO have become quite a hit among health-conscious individuals around the world.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

If you have no experience with edibles, you can be easily overwhelmed if you have to purchase some. In the United States, all types of dosages and types of edibles are available, and a bad purchase may lead to bad highs. Despite this, some marijuana users enjoy edibles so much that they choose edibles over all other cannabis consumption methods. Some people assert that edibles are healthier than smoking and vaping with regard to the lungs, plus they produce stronger results. Edibles may also induce a stronger response in the mind or body as well as potentially provide more pain relief.

Still, one can be easily intimidated by edibles. Here are a few basics that a new user should know to help make informed purchasing decisions.

Extracts vs. Cannabutter

You can infuse your food using marijuana in various ways, mainly with extracts and cannabutter. When oil or butter is infused with cannabis, cannabutter is produced. This mixture can then be used to make chocolates, brownies, and more. Cannabutter encompasses the limitations and benefits of the cannabis flower, which provides the consumer with the complete spectrum of cannabinoids. This means edibles made using cannabutter have CBD, THC and more, which results in unpredictable effects.

In contrast, edibles made using extracts are more targeted. Edible makers can isolate CBD or THC in a lab, and add them to edibles later. This allows these manufacturers to make products that are more consistent and reliable. For individuals who have a specific effect in mind, edibles made with extracts are a good option.

To buy or to make?

If you’re new to edibles, then your best option would be to purchase edibles. However, if you would prefer to make your own edibles, it’s vital that you find a recipe that suits you and stick to it. It is important to note that the entire process will take some time, and that your marijuana  harvest must be decarboxylated.

You should also keep in mind that because you’ll be consuming marijuana through your stomach, there may be a delayed response. Therefore, it’s important to be patient and pace yourself. Avoid consuming more edibles because you aren’t feeling the high yet. It takes a while, but it will come.

Taste

Additionally, the taste depends on the edible. Edibles made with extracts usually taste less like weed as compared to those prepared with cannabutter. To make sure what you get is what you prefer, you can ask your budtender to explain in detail the contents of your edible.

One interesting company worthy of giving some attention to is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). The company was initially set up to produce the best-tasting enhanced water, and WTER has now branched out into making broad and full-spectrum, hemp-infused products.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

In a study published in the “IEEE Sensors Journal” on Sept. 25, 2020, scientists developed a sensor that can be integrated in dental implants to monitor bone growth. This avoids the need for multiple X-rays of the jaw.

Presently, dentists use X-rays to observe jaw health after a patient gets a dental implant. Dental X-rays require low doses of radiation, and we all know that undergoing too many X-rays isn’t good for human health. This new sensor, on the other hand, not only passively monitors bone growth but also reduces the frequency with which patients neet X-rays after receiving dental implants. This reduced need for X-rays is a main motivation for designing the sensor.

Professor Alireza Hassanzadeh and two graduate students, all from the Shahid Beheshti University in Tehran, are the scientists behind this innovative creation. The sensor monitors bone growth by measuring the changes in capacitance. The group developed two designs: one for short-term monitoring and another for the long term.

These sensors were created using poly-ether-ether-ketone and titanium. Those materials are integrated into the dental implant through microfabrication techniques. The sensors consume very little energy, have a high information-processing rate and perform steadily. Additionally, the sensors do not need any batteries and usually start passively monitoring changes in the surrounding electrical field as soon as the dental implant has been embedded into the jaw.

Hassanzadeh explains that as the bone forms around the sensor and dental implant, the capacitance of the sensor changes. This indicates how, over a period of time, the surrounding bone growth changes. The changes noted in capacitance as a result of bone growth are then communicated to a reader device, which sends the measurements to a data logger through a wireless inductive link.

In the study, the scientists tested the sensors in the jaw bone and femur of a cow. Hassanzadeh states that their findings showed that the sensor’s capacitance value was directly affected by the amount of bone growth surrounding the dental implant.

Hassanzadeh also noted that the sensor needed to be optimized for different implant sizes and shapes and that clinical trials needed to be performed with different types of dental implant patients in order to gain additional data. He added that the research team planned to commercialize the sensor after it had received approval from the necessary authorities, including the FDA, and after additional clinical tests were carried out.

One interesting biomedical technology company that you should watch is Processa Pharmaceuticals Inc. (NASDAQ: PCSA). The company focuses on identifying unmet medical needs for which there isevidence of viable solutions. The company then develops products to address those unmet needs.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

If you’ve been thinking about buying a plug-in car to reduce your reliance on fossil fuels, you aren’t alone. The past few years have seen an increasing number of consumers with interest in battery electric vehicles (“EVs”) and plug-in vehicles that don’t rely solely on gasoline. However, while conventional vehicles mostly focus on hardware, plug-ins employ software as well, making the shopping experience quite different.

If you’ve never driven such a vehicle, you’ll want to identify some key differences between EVs and more conventional autos. Apart from the different terminology used with plug-in cars, there are some considerations you wouldn’t have to make for a conventional vehicle. To ensure your shopping experience is as stress-free and productive as possible, consider the following advice:

Research different models of plug-in EVs. If you aren’t sure which plug-in car to buy, you can check manufacturer websites or Edmunds, an online resource for automotive information, for reviews of popular plug-in EVs. The Federal Energy Department also has an interactive Advanced Cars and Fuels tool that lets you do side-by-side comparisons of various plug-in electric cars.

Read up on range. A plug-in EV’s range refers to how far it can drive on a single charge. Although the Federal Environment Protection Agency provides range estimates for pure electric and plug-in EVs, the estimated range can be significantly reduced by high-speed driving, extreme cold and heat. You will have to consider how and where you will drive the vehicle to get a good idea of what the real-world range will be for you. Most plug-in EVs have an electric range of 10–40 miles on a single charge before the internal combustion engine or generator kicks in.

Find economic incentives. To increase the adoption of EVs and plug-in hybrids, government authorities offer incentives to make them more affordable. Check out the Department of Energy’s fueleconomy.gov, which has an up-to-date list of which plug-in EVs qualify for credits. Additionally, plenty of state and local incentives exist, include reduced electricity rates, free parking, carpool lane use, assistance buying home chargers, cash rebates and tax credits.

However, these incentives aren’t offered by every state, and they change frequently. You can use resources such as Plug In America’s interactive state and federal incentives maps to check whether your state offers such incentives. You can also call your local city government to see if you are eligible for local benefits that aren’t on the National Council or Plug In America lists.

Know your charging options. Will you install a home charger or will you charge at the office? Are there public chargers close to where you live or work? The dealership will most likely recommend a charging station, but you can also shop around and compare prices with the stations the dealership suggests. For reliable information on home chargers, check out GoElectricDrive.org, a site that is maintained by the Electric Drive Transportation Association.

The EV industry is in the intersection between technology and hardware, and one firm you should watch in this regard is Net Element (NASDAQ: NETE). While the company’s focus has been on providing global financial solutions, Net Element recently announced that it was merging with Mullen Technologies Inc., a California-based EV manufacturer.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

The use of artificial intelligence (AI) in the development of coronavirus vaccines, which started barely three months after the virus was first identified in China, has revolutionized the way vaccines are developed.

According to the World Health Organization, in September 34 different vaccines were being tested in humans and an additional 145 vaccine candidates had tests being conducted in the lab or on animals. These are surprising numbers, especially considering that it takes years, sometimes decades, to develop a vaccine. Up until the COVID-19 outbreak, the mumps vaccine was the fastest-produced vaccine with a four-year record of development, from sample collection to its marketed form.

Currently, laboratories are looking into eight different types of coronavirus vaccine. These include experimental ones that involve the use of genetic material, i.e., RNA and DNA vaccines, and traditional ones created by using inactivated viruses as well as others that are based on biological agents or special proteins.

Computational analyses and machine-learning systems have played a crucial role in the quest for a SARS-CoV-2 vaccine. These tools help researchers understand the makeup of a virus and other vital information while also predicting the virus’s components that will give rise to an immune response. These systems also help researchers understand experimental data and track the genetic mutations of a virus over time. This information helps determine the value of the vaccine in the years to come.

Researchers are looking forward to a time when computational techniques, through the use of AI, could help solve vaccine challenges such as discovering an effective HIV vaccine. However, despite its advantages, AI cannot speed up or replace the most important and time-consuming part of vaccine development, i.e., animal and human trials. This requires significant human effort, with thousands of participants, health-care workers and scientists all documenting their experiences with different vaccines in the present time.

Unlike in the past, developing vaccines in today’s day and age is largely an information-intensive venture. The use of AI helps makes this process easier as machine-learning tools can make crucial predictions, based on training data sets that are collected from pathogens. While AI is helpful, it cannot replace the time-consuming processes that go into vaccine development.

Additionally, AI can’t predict the outcome of human trials. However, it can certainly make it easier to understand the data collected from these experiments by more quicky and efficiently analyzing all the parameters and locating patterns. As a growing number of potential vaccines advance to the second and third phases of clinical trials, thousands of participants will be involved, and AI systems will be crucial in helping analyze immunological and clinical data.

AzurRx BioPharma Inc. (NASDAQ: AZRX) is an interesting biopharmaceutical company you should watch. The company focuses on leveraging recombinant proteins to develop therapies for gastrointestinal diseases.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.